Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.71 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.71 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.61 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.60 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.60 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.57 |
| ▸ | HRH1 | P35367 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28494404 | 0.98 | TDP1 (0.69) | TDP1L3MBTL1CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL30672504 | 0.98 | — | — | |
| SCHEMBL173147 | 0.98 | — | — | |
| SCHEMBL11563304 | 0.96 | TDP1 (0.71) | TDP1L3MBTL1CHRNA7CHRNB2CHRNA4 | |
| Bromide SCHEMBL14801915 | 0.96 | TDP1 (0.71) | TDP1L3MBTL1CHRNA7CHRNB2CHRNA4 | |
| Sulfuric Acid SCHEMBL28849514 | 0.87 | TDP1 (0.61) | TDP1L3MBTL1CHRNA7CHRNB2CHRNA4 | |
| Acetic Acid SCHEMBL30330124 | 0.87 | TDP1 (0.61) | TDP1L3MBTL1CHRNA7CYP1A2TBXAS1 | |
| Ammonia Solution, Strong SCHEMBL6014613 | 0.86 | TDP1 (0.96) | TDP1L3MBTL1CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL20045569 | 0.85 | TDP1 (0.74) | TDP1L3MBTL1CHRNA7CHRNB2CHRNA4 | |
| SCHEMBL681571 | 0.85 | TDP1 (0.89) | TDP1L3MBTL1CHRNA7CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111163761-A | Targeted drugs related to trimethylamine and/or trimethylamine-N-oxide | 普梭梅根公司 | 2020-05-15 | — | — | CN | claimed |
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | K AND K BIOSCIENCE, INC. (US) | 2006-03-16 | — | — | US | claimed |
| EP-1343497-A4 | $g(D)?2 ,-1,2,3-TRIAZOLINE ANTICONVULSANTS AND THEIR ACTIVE METABOLITE ANALOGUES, THE AMINOALKYLPYRIDINES, ARE EXCITATORY AMINO ACID ANTAGONISTS AND ANTIISCHEMIC AGENTS, USEFUL IN THE TREATMENT OF CEREBRAL ISCHEMIA RESULTING FROM STROKE | K AND K BIOSCIENCES INC (US) | 2005-01-26 | — | — | EP | claimed |
| US-20040073039-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | K AND K BIOSCIENCES, INC. | 2004-04-15 | — | — | US | claimed |
| EP-1343497-A1 | $g(D)?2 ,-1,2,3-TRIAZOLINE ANTICONVULSANTS AND THEIR ACTIVE METABOLITE ANALOGUES, THE AMINOALKYLPYRIDINES, ARE EXCITATORY AMINO ACID ANTAGONISTS AND ANTIISCHEMIC AGENTS, USEFUL IN THE TREATMENT OF CEREBRAL ISCHEMIA RESULTING FROM STROKE | K and K Biosciences, Inc. (US) | 2003-09-17 | — | — | EP | claimed |
| US-20020111371-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | K AND K BIOSCIENCES, INC. | 2002-08-15 | — | — | US | claimed |
| WO-2002036119-A1 | Δ2,-1,2,3-TRIAZOLINE ANTICONVULSANTS AND THEIR ACTIVE METABOLITE ANALOGUES, THE AMINOALKYLPYRIDINES, ARE EXCITATORY AMINO ACID ANTAGONISTS AND ANTIISCHEMIC AGENTS, USEFUL IN THE TREATMENT OF CEREBRAL ISCHEMIA RESULTING FROM STROKE | K AND K BIOSCIENCES, INC. (US) | 2002-05-10 | — | — | WO | claimed |
| CN-111163761-A | Targeted drugs related to trimethylamine and/or trimethylamine-N-oxide | 普梭梅根公司 | 2020-05-15 | — | — | CN | disclosed |
| CN-105209435-B | Compound comprising pyridine or pyrazine | 3M创新有限公司 | 2018-02-02 | — | — | CN | disclosed |
| CN-105209435-A | Pyridine- or pyrazine-containing compounds | 3M INNOVATIVE PROPERTIES CO | 2015-12-30 | — | — | CN | disclosed |
| EP-2382274-B1 | AQUEOUS COATING COMPOSITION COMPRISING PYRIDINE GROUP-CONTAINING ELECTROCOAT RESIN | BASF COATINGS GMBH (DE) | 2015-04-22 | — | — | EP | disclosed |
| CN-102272246-B | Pyridine group-containing electrocoat resin | BASF COATINGS GMBH | 2014-09-17 | — | — | CN | disclosed |
| CN-102272246-A | Pyridine group-containing electrocoat resin | — | 2011-12-07 | — | — | CN | disclosed |
| US-6448277-B2 | ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS | NOVARTIS AG (CH) | 2002-09-10 | — | — | US | disclosed |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | NOVARTIS AG (CH) | 2002-02-14 | — | — | US | disclosed |
| EP-0900207-B1 | PYRAZINONE THROMBIN INHIBITORS | MERCK & CO INC (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-1129075-A1 | N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2001-09-05 | — | — | EP | disclosed |
| WO-2000027820-A1 | N-ARYL(THIO)ANTHRANILIC ACID AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS VEGF RECEPTOR TYROSINE KINASE INHIBITORS | NOVARTIS AG (CH) | 2000-05-18 | — | — | WO | disclosed |
| CN-1222909-A | Pyrazinone thrombin inhibitors | MERCK & CO INC (US) | 1999-07-14 | — | — | CN | disclosed |
| US-5866573-A | Pyrazinone thrombin inhibitors | MERCK & CO., INC. (US) | 1999-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058357-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | SIGMAR1, GRM1, GRIN2C | TDP1 3769/4885L3MBTL1 1503/4885CHRNA7 186/4885 |
| US-20040073039-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | SIGMAR1, GRM1, GRIN2C | TDP1 3458/4885L3MBTL1 1507/4885CHRNA7 223/4885 |
| US-20020019414-A1 | N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors | AXL, TYRO3, KDR | TDP1 2775/4885L3MBTL1 4472/4885CHRNA7 3633/4885 |
| US-20020111371-A1 | Delta2-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke | SIGMAR1, GRM1, GRIN2C | TDP1 3458/4885L3MBTL1 1507/4885CHRNA7 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.